Advanced Biomedical Technologies, Inc. (OTCMKTS: ABMT) is a Massachusetts‐based biotechnology company dedicated to the development, manufacture and commercialization of plasma‐derived and recombinant immunotherapeutics, vaccines and surgical biomaterials. Founded in the early 1990s and headquartered in Beverly, the company combines proprietary fractionation processes with recombinant technology to address critical needs in trauma care, orthopedics, wound healing and infectious disease. Its FDA‐licensed facility supports the production of human fibrin sealants, lyophilized plasma and monoclonal antibody products.
The company’s portfolio includes plasma‐derived products such as fibrin sealant systems used in surgical hemostasis and wound management, as well as high‐potency intravenous immunoglobulins designed for passive immunization against hepatitis B. In parallel, its research and development efforts focus on next‐generation immunotherapies, including oncolytic virus candidates for solid tumors and vaccine constructs targeting novel pathogens. Advanced Biomedical Technologies also offers contract manufacturing services to strategic partners seeking to scale complex biologics under cGMP conditions.
Serving hospital networks, government agencies and biopharma collaborators in North America, Europe and select Asia‐Pacific markets, the company maintains strategic alliances with both academic research centers and U.S. federal health agencies. These partnerships support ongoing clinical programs and expedite regulatory approvals for emergency use and seasonal indications. Advanced Biomedical’s global distribution channels and custom‐formulation capabilities enable rapid response to public health emergencies, including emerging viral outbreaks.
Advanced Biomedical Technologies is guided by an executive leadership team with decades of collective experience in plasma fractionation, regulatory affairs and commercial strategy. The board and management draw on backgrounds at leading pharmaceutical firms and federal research institutions, ensuring scientific rigor and operational excellence. With a focus on innovation and patient safety, the company continues to expand its pipeline of life‐saving therapies and advanced biomaterials for a range of medical specialties.
AI Generated. May Contain Errors.
